ANXA1 and prostate carcinoma: Recent studies provide evidence linking ANXA1 as an endogenous inhibitor of NF-κB that can be induced by glucocorticoids and modified nonsteroidal anti-inflammatory drugs (NSAIDs) in colon and prostate cancer cells44.